tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KZR Stock Latest News

Positive Phase 2 Trial Results and Regulatory Progress Bolster Buy Rating for Kezar Life Sciences
RatingsPositive Phase 2 Trial Results and Regulatory Progress Bolster Buy Rating for Kezar Life Sciences
17d ago
KZR
Kezar Life Sciences Advances in Autoimmune Hepatitis Trials
PremiumCompany Announcements
Kezar Life Sciences Advances in Autoimmune Hepatitis Trials
17d ago
KZR
Kezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)
PremiumThe Fly
Kezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)
18d ago
KZR
Cautious Hold on Kezar Life Sciences Amid Zetomipzomib Developments and Market Uncertainties
PremiumRatings
Cautious Hold on Kezar Life Sciences Amid Zetomipzomib Developments and Market Uncertainties
2M ago
KZR
Kezar Life Sciences lifts partial clinical hold on PORTOLA Phase 2a trial
PremiumThe Fly
Kezar Life Sciences lifts partial clinical hold on PORTOLA Phase 2a trial
2M ago
KZR
Kezar Life Sciences Holds Annual Stockholders Meeting
PremiumCompany AnnouncementsKezar Life Sciences Holds Annual Stockholders Meeting
2M ago
8K
KZR
Kezar Life Sciences Reports Positive Trial Results
Premium
Company Announcements
Kezar Life Sciences Reports Positive Trial Results
3M ago
KZR
Kezar Life Sciences: Promising Phase II Results and Strategic Developments Support Buy Rating
Premium
Ratings
Kezar Life Sciences: Promising Phase II Results and Strategic Developments Support Buy Rating
4M ago
KZR
Kezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65)
PremiumThe Fly
Kezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65)
4M ago
KZR
Kezar Life Sciences Appoints New Principal Accounting Officer
PremiumCompany Announcements
Kezar Life Sciences Appoints New Principal Accounting Officer
5M ago
8K
KZR
Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating
PremiumRatings
Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating
5M ago
KZR
Kezar Life Sciences price target lowered to $7 from $9 at Wells Fargo
PremiumThe Fly
Kezar Life Sciences price target lowered to $7 from $9 at Wells Fargo
5M ago
KZR
Kezar Life Sciences Reports Promising AIH Trial Results
PremiumCompany AnnouncementsKezar Life Sciences Reports Promising AIH Trial Results
5M ago
KZR
Promising Clinical Trial Results and Safety Profile Justify Buy Rating for Kezar Life Sciences
Premium
Ratings
Promising Clinical Trial Results and Safety Profile Justify Buy Rating for Kezar Life Sciences
5M ago
KZR
Kezar Life Sciences reports topline results from PORTOLA trial
Premium
The Fly
Kezar Life Sciences reports topline results from PORTOLA trial
5M ago
KZR
Kezar Life Sciences files $400M mixed securities shelf
PremiumThe Fly
Kezar Life Sciences files $400M mixed securities shelf
7M ago
KZR
Kezar Life Sciences price target lowered to $9 from $11 at Wells Fargo
PremiumThe Fly
Kezar Life Sciences price target lowered to $9 from $11 at Wells Fargo
9M ago
KZR
Kezar Life Sciences reports Q3 EPS ($2.78), consensus ($3.15)
PremiumThe Fly
Kezar Life Sciences reports Q3 EPS ($2.78), consensus ($3.15)
10M ago
KZR
Kezar Life Sciences trading halted, news pending
PremiumThe Fly
Kezar Life Sciences trading halted, news pending
10M ago
KZR
Kezar Life Sciences announces 1-for-10 reverse stock split
PremiumThe FlyKezar Life Sciences announces 1-for-10 reverse stock split
10M ago
KZR
Kezar board rejects Concentra proposal, adopts stockholder rights plan
Premium
The Fly
Kezar board rejects Concentra proposal, adopts stockholder rights plan
11M ago
KZR
Kezar Life Sciences reports PORTOLA trial may proceed, termination of PALIZADE
Premium
The Fly
Kezar Life Sciences reports PORTOLA trial may proceed, termination of PALIZADE
11M ago
KZR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >